பிரையன் விஸ்கவுன்ட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பிரையன் விஸ்கவுன்ட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பிரையன் விஸ்கவுன்ட் Today - Breaking & Trending Today

Applied DNA Secures Amendment to Master Services Agreement and Fourth Blanket Purchase Order from Linea™ COVID-19 Assay Kit Customer

Applied DNA Secures Amendment to Master Services Agreement and Fourth Blanket Purchase Order from Linea™ COVID-19 Assay Kit Customer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jamesa Hayward , Master Services Agreement , Sciences Inc , Drug Administration , Clinical Laboratory Improvement Amendments , Securities Exchange , York State Department Of Health , Wall Street , Continuing Access , Assay Kit , Pooled Surveillance Testing Program , Polymerase Chain Reaction , Assay Kits , Pooled Surveillance , Russell Microcap , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , New York State Department , Emergency Use Authorization , Annual Report , Brian Viscount , அறிவியல் இன்க் , மருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள் , பத்திரங்கள் பரிமாற்றம் , யார்க் நிலை துறை ஆஃப் ஆரோக்கியம் ,

Applied DNA Sciences, Inc.: Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA COVID-19 Vaccine Candidate for Feline Veterinary Market

(2)
- Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models
- Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company ), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. ( Evvivax ), today announced the initiation of Phase I of a two-phase clinical trial to evaluate a LinearDNA COVID-19 vaccine candidate for the feline veterinary market. The goal of the trial is to evaluate the vaccine candidate as a strategy for the prevention of SARS-CoV-2, the virus that causes COVID-19, in feline companions of humans that may mitigate the animals as a potential reservoir for infections in humans. If successful, the clinical trial will also serve as an important initial validation of LinearDNA, Appl ....

United States , Joseph Impellizeri , Jamesa Hayward , Luigi Aurisicchio , Us Department Of Agriculture , Sciences Inc , Drug Administration , Veterinary Oncology Services At Guardian Specialists , Securities Exchange , American Veterinary Medical Association , Plant Health Inspection Service , Candidate Previously Demonstrated Antibodies , T Cell Response , Mouse Models , Initial Validation , Large Mammals , Potential Advantages , Polymerase Chain Reaction , Takis Biotech , Veterinary Oncology Services , Guardian Veterinary Specialists , Supervising Investigator , American College , Veterinary Internal Medicine , Russell Microcap , Looking Statements ,

Applied DNA Achieves Program Milestone in Development of Linear DNA Veterinary COVID-19 Vaccine

Press release content from Business Wire. The AP news staff was not involved in its creation.
Applied DNA Achieves Program Milestone in Development of Linear DNA Veterinary COVID-19 Vaccine
February 2, 2021 GMT
STONY BROOK, N.Y. (BUSINESS WIRE) Feb 2, 2021
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it has qualified a freeze-dried (lyophilized) form of its LinearDNA™ COVID-19 vaccine candidate for its upcoming feline clinical trial. Lyophilization renders the vaccine candidate shelf-stable and convenient to ship globally at room temperature, thereby circumventing a key logistical limitation inherent to all existing nucleic acid-based (human and veterinary) vaccines. Quantities of the lyophilized vaccine candidate were manufactured and shipped packaged in vials to its program development partner, EvviVax, S.R.L. (“EvviVax”) for preclinical potency, ste ....

United States , Jamesa Hayward , Us Department Of Agriculture , Sciences Inc , Drug Administration , Securities Exchange , Polymerase Chain Reaction , Russell Microcap , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Annual Report , Brian Viscount , Business Wire , ஒன்றுபட்டது மாநிலங்களில் , அறிவியல் இன்க் , பத்திரங்கள் பரிமாற்றம் , பத்திரங்கள் நாடகம் , பத்திரங்கள் பரிமாற்றம் நாடகம் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஆண்டு அறிக்கை , பிரையன் விஸ்கவுன்ட் , வணிக கம்பி ,